Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia
Recruitment status was: Not yet recruiting
PURPOSE: We determined whether Synergo therapy- intravesical chemotherapy instillation combined with hyperthermia instillation is associated with elevated prostate specific antigen (PSA). MATERIALS AND METHODS: We will treat 25 consecutive patients with bladder cancer with a 6-week course of Synergo therapy, followed by cystoscopy at 6 weeks. Blood samples for PSA determination will obtain before each synergo therapy application and at cystoscopy with each patient also serving as a control.
Evaluating changes in PSA level in patients undergoing treatment with Synergo delivered local hyperthermia combined with intravesical instillation of Mitomycin C for adjuvant treatment or pt. with recurrent tu of bladder post TURT with BCGtreatment.
|Bladder Cancer||Device: SYNERGO Device: SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
|Study Design:||Time Perspective: Prospective|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00491296
|Contact: doron perez, M.D.||+firstname.lastname@example.org|
|Afula, Israel, 18100|
|Department of urology||Not yet recruiting|
|Afula, Israel, 18101|
|Contact: doron perez, M.D. +972-4-6495115 email@example.com|
|Principal Investigator:||PEREZ DORON, M.D.||HAEMEK MEDICAL CENTER, UROLOGY DEPARTMENT|
|Principal Investigator:||Perez Doron, M.D||haemek medical center|